Supernus Pharmaceuticals reported $400.91M in Debt for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Debt Change
Aerie Pharmaceuticals AERI:US $ 312.13M 0.45M
Ani Pharmaceuticals ANIP:US $ 286.94M 0.21M
Aurora Cannabis Inc ACB:CN 388.14M 26.31M
Bristol Myers Squibb BMY:US $ 42060M 2912M
Canopy Growth Corp WEED:CN C$ 1.46B 112.65M
Cara Therapeutics CARA:US $ 0 0
Corcept Therapeutics CORT:US $ 0M 0M
Eisai 4523:JP Y 94902M 9M
Eli Lilly And LLY:US $ 16813.8M 305M
Endo International Ordinary Shares ENDP:US $ 8065.3M 25.32M
Horizon Pharma HZNP:US $ 2566.99M 1.75M
JAZZ PHA JAZZ:US $ 6021M 2.87M
Lannett LCI:US $ 610.08M 6.6M
Marinus Pharmaceuticals MRNS:US $ 69.93M 29.12M
Pacira Pharmaceuticals PCRX:US $ 755.65M 167.77M
Perrigo Ordinary Shares PRGO:US $ 4116.9M 601.7M
Revance Therapeutics RVNC:US $ 396.1M 53.64M
Supernus Pharmaceuticals SUPN:US $ 400.91M 0.53M
Teva Pharmaceutical Industries TEVA:US $ 22082M 835M
United Therapeutics UTHR:US $ 800M 0M
Xeris Pharmaceuticals Inc XERS:US $ 138.07M 429K